ISSN: 2322 - 0902 (P)

ISSN: 2322 - 0910 (O)

International Journal of Ayurveda
and Pharma Research
Research Article

CLINICAL EVALUATION OF JATAMAMSI CHURNA IN THE MANAGEMENT OF ESSENTIAL HYPERTENSION

D.Venkata Krishna Naik1*, Vasu ray1, J.Srinivasulu2, S.Ramalingeswara rao2
*1PG Scholar, 2Reader, Dept. of Kayachikitsa, Dr.BRKR.Govt. Ayurvedic College & Hospital, Hyderabad, Telangana, India.
ABSTRACT
In an open clinical trial 20 patients of grade-I and grade-II uncomplicated Essential Hypertension of either
sex aged between 25-70 years, were given Jatamamsi Churna in a dose of 10 grams per day in two equal
divided doses for a duration of 60 days. At the end of trial period their systolic blood pressure was reduced
from 148.9 mm of Hg to 132.6 mm of Hg and diastolic blood pressure was reduced from 97.1 mm of Hg to
86.4 mm of Hg. Pulse pressure, mean blood pressure, and various clinical features were also significantly
reduced after the therapy. No untoward effects were reported by any patient and their biochemical and
Hematological parameters also remained within normal limits, both before and after the therapy. Thus trial
drug i.e. Jatamamsi churna may prove an ideal drug for the management of grade-I and grade-II Essential
Hypertension.
KEYWORDS: Essential hypertension, Jatamamsi churna, untoward effects.
INTRODUCTION
Hypertension is emerging as one of important includes alkaloids jatamansone, nardostachone,
public health problem in the developed as well as jatamansicacid, coumarins, lignan, neolignans and
developing countries. In today’s competitive world and sesquiterpenes.[9-10]. So still the quest for safe and ideal
modern life style, anxiety, stress and strain are increasing antihypertensive drug is there. So based on these facts we
alarmingly and influencing the development of various have made an effort to find a safe Anti-Hypertensive
psychosomatic disorders including Hypertension. It is a therapy through an Ayurvedic herbal formulation. The
major risk factor for the development of coronary artery present clinical trial was conducted to evaluate the efficacy
disease, stroke, congestive heart failure and renal of Jatamamsi Churna[11] in the management of grade-I and
disorders . Hypertension affects approximately one
[1] grade-II essential hypertension.
billion individual’s word wide. Recent data from Inclusion Criteria
Framingham Heart study suggest that individuals who are Twenty cases of grade-I and grade-II
Normotensive at the age of 55 have a 90 percent life time Hypertension between 25 to 75 years of age of either sex
risk for developing Hypertension[2]. were included in the trial. Gradation of blood pressure was
In clinical trials, Anti-Hypertensive therapy has done on the basis of recommendations of Joint National
been associated with reduction in stroke incidence Committee on Detection Evaluation and Treatment of High
averaging 35-40 percent; myocardial infarction 20-25 Blood Pressure i.e. JNC-7 as :
percent, and heart failure, more than 50 percent[3]. Recent Table 1: Gradation of blood pressure
clinical trials have demonstrated that effective blood
pressure control can be achieved in most patients who are Category Systolic B.P. in Diastolic BP in
Hypertensive, but the majority will require two or more mm of Hg mm of Hg
Anti-Hypertensive drugs . Presently a number of effective
[4]
Stage-I 140-159 90-99
Anti-Hypertensive drugs are available but they are not free
Stage-II >160 >100
from untoward effects. Beta blockers can cause fatigue,
cold extremities, Bradycardia, heart failure and Exclusion Criteria
Angiotensive converting enzyme inhibitors can cause All the patients of secondary hypertension,
cough, rash, and proteinuria etc. [5] An Anti-hypertensive patients having diastolic BP> 110 mm of Hg and systolic
drug should ideally improve patient’s compliance. Any BP>180 mm of Hg, Hypertension associated with
treatment administered should be directed to not only pregnancy and hypertension along with complications of
control blood pressure, but also prevent target organ target organs.
damage, thereby preserving cardiac and renal functions Material and Methods
which increases patients life span. [6,7] One of the safest and Method of Study
potent anti-hypertensive drug from the reservoir is
Registered patients were given Jatamamsi Churna
Jatamansi churna (Nardostachys jatamansi). It is used
in a dose of 10 grams/day in two equal divided doses and
traditionally in the treatment of nervous headache,
advised it to make as decoction i.e., Kashaya with 5gms of
hypertension, epilepsy, intestinal colic, hysteria and
Churna per dose for 60 days. Patients has been selected
depressive illness.8 More than 25 active principles have
from OPD of Kayachikitsa Dept from Dr.BRKR Govt
been isolated from the rhizome part of this plant which
Ayurvedic College and Hospital, were thoroughly assessed
IJAPR | June 2016 | Vol 4 | Issue 6 92
 Int. J. Ayur. Pharma Research, 2016;4(6):92-94
on the basis of various subjective and objective parameters Observations and Results
after every 15 days till the completion of trial period i.e. 60 Mean systolic blood pressure which was 148.9
days. However change in systolic, diastolic and mean blood mm of Hg before treatment was reduced to 132.6 mm of
pressure was the main criteria of assessment. Patients Hg and mean diastolic blood pressure came down from
were also asked to report untoward effects if any, such as 97.1mm of Hg to 86 mm of Hg after 60 days of therapy.
nausea, vomiting, giddiness, insomnia etc. Base line Reduction in both systolic and diastolic blood pressure
Haematological and Biochemical parameters including was statistically highly significant (P<0.001). Effects of the
TLC, DLC, ESR, Hb, Fasting blood sugar, B. Urea, S. therapy on mean blood pressure, pulse pressure and
Creatinine, Lipid profile, Urine routine and microscopic symptomatology are shown in Table No. 2 and 3
examination were assessed both before and after therapy respectively. Base line haematological and biochemical
to observe the effects of trial drugs on other systems of the parameters at the beginning and end of the study did not
body. show any abnormality (Table No. 4).
Table 2: Effects of the Therapy on Blood Pressure
Variable in BT Mean Score AT 60 % of SD + SE + T P
15 days 30 days 45 days days relief
Systolic BP 148.9 141.1 135.6 133.8 132.6 10.94 12.9 2.8 5.73 <0.001
Diastolic BP 97.1 94.7 88.6 86.6 86.4 11.01 10.18 2.27 4.69 <0.001
Mean BP 113.8 110.6 100.06 98.1 96.2 15.42 25.9 5.7 2.21 <0.05
Pulse Pressure 51.8 49.2 47 47.2 45.2 12.75 10.51 2.3 2.76 <0.05
Table 3: Effects of the Therapy on Clinical Features
Clinical Features Mean Score % of relief SD + SE + T P
BT AT
Headache 1.7 0.45 73.52 0.824 0.184 5.69 <0.001
Santapa 0.4 0.1 75 0.57 0.12 2.51 <0.005
Padadaha 0.25 0.15 40 0.3 0.06 1.49 >0.05
Krishta 1.55 0.2 87.09 0.933 0.20 6.75 <0.001
Bhrama 0.85 0.15 82.15 0.732 0.16 4.27 <0.001
Klama 1.1 0.2 81.81 0.55 0.12 7.2 <0.001
Tamodarshana 0.3 0.1 66.66 0.52 0.11 1.78 >0.05
Prabhuta mutrata 0.25 0.05 80 0.41 0.091 2.18 <0.05
Krodha 0.75 0.2 73.33 0.604 0.13 4.07 <0.001
Table 4: Effects of the Therapy on Biochemical Profile
Variable in Mean Score % of relief SD + SE + T P
BT AT
S.Cholesterol 208 199.8 3.94 6.92 1.54 4.97 <0.001
VLDL 30.35 29.2 3.78 0.98 0.22 5.2 <0.001
LDL 112.5 110.95 1.42 1.56 0.34 4.5 <0.001
HDL 58.9 57.3 2.71 2.68 0.6 5.3 <0.001
S.Triglycerides 153.65 150.15 2.27 2.68 0.6 5.3 <0.001
B.Urea 25.5 24.4 4.3 0.98 0.21 5.2 <0.001
S.Creatinine 0.56 0.52 7.1 0.06 0.12 3.75 <0.001
FBS 87.6 86.4 3.1 0.95 0.21 5.6 <0.001
DISCUSSION
Hypertension is a multifactorial disease. Most of Anti-Hypertensive drug which is potent and safe for long
the patients of uncomplicated Hypertension remain term use.
asymptomatic during early years of the disease. A lot of In this study the trial drug fulfilled all the lacunae
Anti-Hypertensive drugs are available today but none of mentioned above, as it significantly reduced systolic blood
them possess curative potential. Because all the currently pressure by 16.3 mm of Hg, diastolic blood pressure by
available drugs have just palliative effect hence they are 10.7 mm of Hg. Pulse pressure and mean blood pressure
required to be taken throughout the life. Due to this reason were also statistically significantly lowered by 6.6 mm of
untoward effects associated with presently available drugs Hg and 17.6 mm of Hg respectively. Various clinical
are inevitable. Recent clinical trials have demonstrated features except Padadaha and Tamodarshana were also
that majority of the Hypertensive patients require multiple significantly improved after the therapy (Table No. 3).
antihypertensive drugs for optimum blood pressure Hypertension accelerates the development of
control.[4] Due to prolonged multiple drug therapy Atherosclerosis, especially when combined with other risk
annoying untoward effects are further augmented, leading factors such as Dyslipidaemia. After therapy, there was
to decreased compliance in asymptomatic patients. So still marginal reduction in serum total cholesterol, VLDL and
the quest for an ideal and safe Anti-Hypertensive drug is triglycerides. (Table No. 4)
there. Present trial is an attempt to develop an ideal herbal
IJAPR | June 2016 | Vol 4 | Issue 6 Page 93
 D.Venkata Krishna Naik et al. Clinical Evaluation of Jatamamsi Churna in the Management of Essential Hypertension
Animal experimentation has proved the Anti-
Hypertensive activity of Jatamamsi. Pharmacological
studies have also revealed its central depressant action
and vascular smooth muscle relaxation properties. So
probably Anti-Hypertensive action of Jatamamsi is
mediated partly through reduction in cardiac output and
partly through reduction in peripheral resistance. During
the course of treatment all the patients reported a growing
feeling of well being and none of them reported any
untoward effect.
CONCLUSIONS
Optimum blood pressure control is desirable to
reduce long term cardiovascular mortality and morbidity.
The trial drug i.e. Jatamamsi Churna can be an effective and
ideal Anti-Hypertension drug in grade-I and grade-II
essential Hypertension at the prescribed doses. It can be
more useful in the management of essential Hypertension
with associated dyslipidemia. It has been found to be free
from any untoward effects. More studies are desperately
required for thorough assessment of Anti-Hypertensive
potential of trial drug i.e. Jatamamsi.
REFERENCES
1. Lawrence Tierney, Jr. Stephen J. McPhee Maxine A.
Papadakis, Current Medical Diagnosis and Treatment
forty-first edition. Lange Medical Books, 2002; 462-
463.
2. Vasan RS, Beiser A, Seshadris, et. al. Residual life time
risk for developing. Hypertension in middle aged
women and men: The framingham Heart Study. JAMA.
2002; 287 : 1003-10
3. Neal B, Mac Mahon S, Chapman N. Effects of blood
pressure lowering drugs: Results of prospectively
designed overviews of randomised trials. Blood
pressure lowering treatment trials’ collaboration
lancet 2000; 356: 1955-64
4. Black HR, Elliott wj, Neaton JD, et.al. Base line
characteristics and elderly blood pressure control in
the CONVINCE trial. hypertension. 2001; 37; 12-8
5. Siddhart N. Shah. API Text Book of Medicine, 7th
Edition, 2003, 457-459 and 430-432
6. Fagher B., Valind D., Thulin T. End organ damage in
treated severe hypertension : Close relation to
nocturnal blood pressure. J Hum Hyperten 1995; 9(8):
605-10
7. Eugene B.A. text blood of cardiovascular medicine, 5th
Edition, Vol. 1, 1997; 1:807
8. C.P. Khare (Ed.) Indian Medicinal Plants An Illustrated
Dictionary, Springer Science and Business Media, LLC,
Spring Street, New York, NY USA), 2007: 433-434.
9. Arora RB. Nardostachys jatamansi- a chemical,
pharmacological and clinical appraisal. Monograph
Special Series, vol.51, Indian council of Medical
Research, New Delhi: 1965.
10. Bagchi, A., Oshima, Y. and Hikino, H. Neolignans and
lignans of Nardostachys jatamansi roots. Planta Med,
1991; 57: 96–97.
11. Dravyaguna vignana (Fundamental Principles of
Pharmaco therapeutics in Ayurveda) Vol 2 By
Dr.J.L.N.Sastry; Chaukhamba Orientalia, Varanasi,
1982.

Cite this article as: *Address for correspondence

D.Venkata Krishna Naik, Vasu ray, J.Srinivasulu, S.Ramalingeswara rao. Dr D.Venkata Krishna Naik
Clinical Evaluation of Jatamamsi Churna in the Management of Essential PG Scholar,
Hypertension. International Journal of Ayurveda and Pharma Research. Dept. of Kayachikitsa
2016;4(6):92-94. Dr.BRKR.Govt. Ayurvedic College &
Source of support: Nil, Conflict of interest: None Declared Hospital, Hyderabad, Telangana, India.
Mob: 09652739467
Email: krishna.kittunk@gmail.com

Available online at: http://ijapr.in 94